PPARα agonist fenofibrate attenuates iron-induced liver injury in mice by modulating the Sirt3 and β-catenin signaling-Reference-Cited by-同舟云学术

PPARα agonist fenofibrate attenuates iron-induced liver injury in mice by modulating the Sirt3 and β-catenin signaling

Published:2021-09-01 Issue:3 Volume:321 Page:G262-G269
ISSN:0193-1857
Container-title:American Journal of Physiology-Gastrointestinal and Liver Physiology
language:en
Short-container-title:American Journal of Physiology-Gastrointestinal and Liver Physiology

Author:

Mandala Ashok¹,Chen William J.¹,Armstrong Austin¹,Malhotra Milan R.¹,Chavalmane Sanmathi²,McCommis Kyle S.³,Chen Anping⁴,Carpenter Danielle⁴,Biswas Pratim⁵,Gnana-Prakasam Jaya P.¹³^ORCID

Affiliation:

1. Department of Ophthalmology, Saint Louis University, St. Louis, Missouri

2. Department of Energy, Environmental and Chemical Engineering, Washington University, St. Louis, Missouri

3. Department of Biochemistry & Molecular Biology, Saint Louis University, St. Louis, Missouri

4. Department of Pathology, Saint Louis University, St. Louis, Missouri

5. Department of Engineering, University of Miami, Coral Gables, Florida

Abstract

Hepatic intracellular iron accumulation has been implicated in the pathophysiology of chronic liver diseases. In this study, we identified a novel mechanism involved in the progression of fibrosis. Excess iron accumulation in liver caused downregulation of PPARα-Sirt3-Wnt signaling leading to fibrosis. This work has significant translational potential as PPARα agonist fenofibrate could be an attractive therapeutic drug for the treatment of liver disorders associated with iron overload.

Funder

American Heart Association

HHS | NIH | National Eye Institute

Publisher

American Physiological Society

Subject

Physiology (medical),Gastroenterology,Hepatology,Physiology

Link

https://journals.physiology.org/doi/pdf/10.1152/ajpgi.00129.2021

Reference30 articles.

1. Balancing Acts

2. Iron overload syndromes and the liver